TransMedics Group, Inc. $TMDX Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 51.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,100 shares of the company's stock after selling 2,226 shares during the quarter. Vontobel Holding Ltd.'s holdings in TransMedics Group were worth $281,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Opal Wealth Advisors LLC acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $26,000. Smartleaf Asset Management LLC increased its position in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after acquiring an additional 135 shares during the period. Quarry LP increased its position in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after acquiring an additional 278 shares during the period. Sound Income Strategies LLC purchased a new stake in shares of TransMedics Group during the second quarter worth $48,000. Finally, Hager Investment Management Services LLC increased its position in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after acquiring an additional 205 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Trading Up 1.2%

NASDAQ:TMDX opened at $112.61 on Thursday. The stock's 50 day moving average price is $116.46 and its 200 day moving average price is $112.69. The company has a market capitalization of $3.84 billion, a PE ratio of 58.35 and a beta of 2.08. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $145.50.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. The business had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company's revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on TMDX shares. Zacks Research cut TransMedics Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Wall Street Zen cut shares of TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Stifel Nicolaus began coverage on shares of TransMedics Group in a report on Thursday, September 4th. They issued a "hold" rating and a $115.00 target price on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $142.00 price objective on shares of TransMedics Group in a research report on Tuesday. Finally, Morgan Stanley increased their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $127.18.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.